• Who We Are
    • Letter from the CEO
    • About Us
    • Our Team
  • Science
  • Pipeline
    • Pipeline Overview
    • NVD-003
    • NVD-X3
  • Patients
  • Investors
  • Contact
  • Careers
What's New
  • Home
  • Who We Are
    • Letter from the CEO
    • About Us
    • Our Team
  • Science
  • Pipeline
    • Pipeline Overview
    • NVD-003
    • NVD-X3
  • Patients
  • Investors
  • What’s New
  • Contact
  • Careers

Novadip shares positive 12-month results from phase 1b/2a trial with NVDX3 in trauma

by Novadip | Feb 20, 2025 | Press Releases, Featured News

At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union No adverse events related to NVDX3 observed A phase 2b/3 trial in 2-level cervical spine...

Novadip reports 12-month results from phase 1b/2a trial of NVD003 to treat rare pediatric disease Congenital Pseudarthrosis of the Tibia

by Novadip | Jan 31, 2025 | Press Releases

88% efficacy demonstrated across all patients (n=17) treated withNVD003 to date (nine adults with bone non-union and eight childrenwith Congenital Pseudarthrosis of the Tibia)100% efficacy demonstrated when mechanical stability of fracture isachievedCompany now...

Novadip appoints Drew Trivisonno to the board of directors to drive financial and business development

by Novadip | Jan 30, 2025 | Press Releases

Seasoned financial executive with over 30 years’ experience -including senior management of orthopedic startups – to supportNovadip in its financing rounds and expansion into US orthopedicsmarket Mont Saint-Guibert, Belgium, January 9, 2025 – Novadip...

Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion

by Novadip | Nov 22, 2024 | Press Releases

Built upon robust preclinical and clinical datasets, NVDX3 has potential to replace existing allogenic bone grafting materials – providing patients with complex comorbidities better bone fusion success Phase 2b/3 expected to begin enrollment in H2 2025 in the US...

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a stem-cell derived bone graft alternative

by Novadip | Oct 24, 2024 | Press Releases

At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing  Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix...
« Older Entries
Next Entries »

Stay Updated by Joining Our Email List

Success!

Subscribe

NOVADIP

Novadip is advancing the standard of care
in bone and tissue regenerative medicine

info@novadip.com

+32 (10) 779 220

Navigation

Who We Are

Our Science

Our Pipeline

Patients

Investors

What’s New

Get In Touch

Contact

Careers

Legal

Privacy Policy

Cookie Policy

Information Notice

Proposed Expanded Access Policy

©2022 NOVADIP. All Rights Reserved.

  • Follow